Khindivi is the sole FDA-approved hydrocortisone oral solution and is available in a 1mg/ml concentration. This formulation ...

KHINDIVI is the first and only FDA-approved hydrocortisone oral solution • Commercial launch expected the week of June 2 nd • ...

The Food and Drug Administration (FDA) has approved Khindivi ™ (hydrocortisone) oral solution as a replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency.

Eton Pharmaceuticals, Inc (“Eton” or“the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S.

Use a different hydrocortisone-containing drug product for stress dosing. Adrenal Crisis: Undertreatment or sudden discontinuation of therapy with KHINDIVI may lead to symptoms of adrenal ...

KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocort ...

Eton Pharmaceuticals’ NDA for Khindivi receives US FDA nod for oral solution formulation: Deer Park, Illinois Friday, May 30, 2025, 13:00 Hrs [IST] Eton Pharmaceuticals, Inc, an ...

Eton Pharmaceuticals (ETON) stock gains as the FDA approved Khindivi its oral hydrocortisone solution for children with adrenocortical insufficiency. Read more here.

Shares of Eton Pharmaceuticals Inc (NASDAQ:ETON) saw a 3.3% boost in premarket trading after the company announced U.S. Food ...

KHINDIVI is the only FDA-approved oral liquid formulation of hydrocortisone, specifically designed for children five years and older who require replacement therapy for adrenocortical insufficiency.